Basilea Pharmaceutica AG (BSLN) — Capital Reinvestment Ratio
Latest as of December 2025:
0.06x
Basilea Pharmaceutica AG (BSLN) has a Capital Reinvestment Ratio of 0.06x as of December 2025, meaning it reinvests 0% of its operating cash flow (CHF39.03 Million) in capital expenditures (CHF2.30 Million). See BSLN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.06x
Capex / Operating Cash Flow
Operating Cash Flow
CHF39.03 Million
CHF
Capital Expenditures
CHF2.30 Million
CHF
Data as of
Dec 2025
Most recent filing
Basilea Pharmaceutica AG Capital Reinvestment Ratio (2005–2025)
This chart tracks Basilea Pharmaceutica AG's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Basilea Pharmaceutica AG (2005–2025)
Year-by-year Capital Reinvestment Ratio for Basilea Pharmaceutica AG from 2005 to 2025. For live market cap and broader valuation context, see BSLN company net worth.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | CHF62.09 Million | CHF2.62 Million | ▲ +83.5% |
| 2024 | 0.02x | CHF74.36 Million | CHF1.71 Million | ▼ -68.3% |
| 2023 | 0.07x | CHF14.24 Million | CHF1.03 Million | ▼ -84.5% |
| 2022 | 0.47x | CHF7.06 Million | CHF3.30 Million | ▲ +1151.9% |
| 2017 | 0.04x | CHF19.01 Million | CHF711.00K | ▲ +319.3% |
| 2012 | 0.01x | CHF148.17 Million | CHF1.32 Million | ▼ -23.3% |
| 2010 | 0.01x | CHF106.64 Million | CHF1.24 Million | ▼ -66.7% |
| 2005 | 0.03x | CHF34.38 Million | CHF1.20 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow